The sharp decline in collaboration revenue and resulting net loss are significant negative developments, despite positive clinical updates. Traders should monitor upcoming clinical data readouts in 2026 as key catalysts, but the financial deterioration suggests increased risk. The cash runway into Q3 2027 provides near-term stability, but future dilution risk may increase if revenue does not recover.
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 26 $12.79entry
- T+1 · 9mo ago −6.72%α −6.27% · $11.93
- T+5 · 9mo ago −9.15%α −8.02% · $11.62
- T+20 · 8mo ago −3.75%α +2.65% · $12.31
- T+60 · 6mo ago −50.66%α −58.42% · $6.31
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Entrada Therapeutics reported financial results for Q4 and full year 2025, showing a significant decline in collaboration revenue and a shift from net income to a net loss compared to the prior year. The company highlighted clinical progress in its DMD and DM1 programs, including a positive DMC recommendation to advance the ELEVATE-44-201 study to a higher dose cohort. Cash runway is expected into Q3 2027 with $295.7 million in cash and marketable securities.
Key Financial Metrics
Key Facts
- Collaboration revenue dropped to $25.4 million in 2025 from $210.8 million in 2024, primarily due to the substantial completion of VX-670 collaboration research activities in Q1 2025.
- Net loss was $143.8 million for 2025 compared to net income of $65.6 million in 2024.
- Cash, cash equivalents, and marketable securities were $295.7 million as of December 31, 2025, down from $420.0 million as of December 31, 2024.
- The Independent Data Monitoring Committee recommended initiating Cohort 2 at a higher dose (12 mg/kg) in the ELEVATE-44-201 study without protocol modifications.
- The company expects to report data from ELEVATE-44-201 Cohort 1 in Q2 2026 and Cohort 2 by year-end 2026.
Financial Impact
Revenue declined by $185.4 million YoY, resulting in a net loss of $143.8 million in 2025 versus net income of $65.6 million in 2024.
Risk Factors
- Significant decline in collaboration revenue with no indication of new major partnerships to replace VX-670 funding.
- Increased R&D and GA expenses are outpacing any new revenue streams, leading to substantial cash burn.
- Clinical trial timelines and outcomes remain uncertain, with no guarantee of regulatory approval even with positive data readouts.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001689375-26-000009 |
| Document: trda-20260226.htm | 0001689375-26-000009 |
| Document: 0001689375-26-000009-index-headers.html | 0001689375-26-000009 |
| Document: 0001689375-26-000009-index.html | 0001689375-26-000009 |
| Document: 0001689375-26-000009.txt | 0001689375-26-000009 |
Track record
21 reports on TRDA
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $4.55 Now $5.00 +9.89% settles Feb 3
- Oct 14, 20264w ago 8-K Bullish 6/10 Entry $4.55 Now $5.00 +9.89% settles Jan 11
- Sep 9, 20269w ago Insider Cluster Bearish 6/10 Entry $6.42 Now $5.00 +22.12% settles Dec 4
- Sep 3, 202610w ago Insider Cluster Neutral 3/10 Entry $7.13 Now $5.00 −29.87% settles Dec 1
- Aug 31, 202611w ago Insider Cluster Neutral 4/10 Entry $7.07 Now $5.00 −29.28% settles Nov 25
- Aug 31, 202611w ago Insider Cluster Neutral 4/10 Entry $7.07 Now $5.00 −29.28% settles Nov 25
- Aug 31, 202611w ago Insider Cluster Neutral 3/10 Entry $7.07 Now $5.00 −29.28% settles Nov 25
- Aug 26, 202611w ago Insider Cluster Neutral 3/10 Entry $7.27 Now $5.00 −31.22% settles Nov 20
- Aug 10, 202614w ago Insider Cluster Neutral 2/10 Entry $7.04 to $5.06 Now $5.00 −28.98% ▼ −28.13% −27.64% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers